Education and Training
Uwe Haberkorn is Head of the Dept. of Nuclear Mecicine at the University Hospital Heidelberg and the Clinical Cooperation Unit Nuclear Medicine at the DKFZ Heidelberg. He studied German Studies and Philosophy in Heidelberg, Marburg and Würzburg. After graduating in Medicine in Marburg, Würzburg and Heidelberg he conducted his MD studies at the DKFZ Heidelberg, and worked as a postdoc at the DKFZ. He received his state doctorate in Nuclear Medicine and since 1998 he leads the the Dept. of Nuclear Medicine and the Clinical Cooperation Unit Nuclear Medicine.
Expertise
The Haberkorn group aims to apply radioactive molecules for the diagnosis and therapy of malignant tumors and the development of novel radiopharmaceuticals using rational design as well as high-throughput methods such as phage and ribosome display with peptide libraries. For many years the group has worked with Molecular Biology and Biotechnology methods for the identification of tumor affine ligands. After successfull evaluation in cell culture and tumor bearing animals these ligands may be transferred into clinical application.
- Diagnosis of malignant tumors with PET/CT
- TumorenEndoradiotherapy of malignant tumors
- Development of new radiopharmaceuticals
Lung Cancer
Feasibility, Tolerability, and Preliminary Clinical Response of Fractionated Radiopharmaceutical Therapy with 213Bi-FAPI-46: Pilot Experience in Patients with End-Stage, Progressive Metastatic Tumors. Helisch A, Kratochwil C, Kleist C, Krämer S, Rosales Castillo JJ, Dendl K, Rathke H, von Goetze I, Schreckenberger M, Jäger D, Lindner T, Mier W, Giesel F, Haberkorn U, Röhrich M.J Nucl Med. 2024 Dec 3;65(12):1917-1922.
1,090 Publications and 5 Years Later: Is FAP-Targeted Theranostics Really Happening?Haberkorn U, Altmann A, Giesel FL, Kratochwil C.J Nucl Med. 2024 Oct 1;65(10):1518-1520.
Diagnostic Potential of Supplemental Static and Dynamic 68Ga-FAPI-46 PET for Primary 18F-FDG-Negative Pulmonary Lesions. Röhrich M, Daum J, Gutjahr E, Spektor AM, Glatting FM, Sahin YA, Buchholz HG, Hoppner J, Schroeter C, Mavriopoulou E, Schlamp K, Grott M, Eichhorn F, Heußel CP, Kauczor HU, Kreuter M, Giesel F, Schreckenberger M, Winter H, Haberkorn U.J Nucl Med. 2024 Jun 3;65(6):872-879.
Impact of 68Ga-FAPI PET/CT on Staging and Oncologic Management in a Cohort of 226 Patients with Various Cancers.Koerber SA, Röhrich M, Walkenbach L, Liermann J, Choyke PL, Fink C, Schroeter C, Spektor AM, Herfarth K, Walle T, Calais J, Kauczor HU, Jaeger D, Debus J, Haberkorn U, Giesel FL.J Nucl Med. 2023 Nov;64(11):1712-1720.
Radiotheranostics in oncology: Making precision medicine possible. Aboagye EO, Barwick TD, Haberkorn U.CA Cancer J Clin. 2023 May-Jun;73(3):255-274.
FAPI PET: Fibroblast Activation Protein Inhibitor Use in Oncologic and Nononcologic Disease. Mori Y, Dendl K, Cardinale J, Kratochwil C, Giesel FL, Haberkorn U.Radiology. 2023 Feb;306(2):e220749.
Dr. Annette Altmann | Leader Biotech group | ||||
Christiane Brenner | Technician | ||||
Vanessa Kohl | Technician | ||||
Marlene Tesch | Technician |
Lung Research - Projects
- Development of new lead structures for tumor-associated surface structures: after identification and validation of proteins with overexpression in tumors high-troughput methods are used to identify peptides which may serve as lead structures for further optimization. These affinity maturated peptides are then evaluated in vitro and in animal experiments. In case of successfull preclinical testing the tracers are then transferred to clinical application.
- Use of tracers for the visualization of activated fibroblasts in animals and patients with lung tumors: for patients with lung tumors PET/CT measurements will be done with radiolabeled FAP (fibroblast activation protein) inhibitors (FAPI) for the staging or the planning of radiation therapy and the impact of FAPI PET on therapy decision will be evaluated.
- Use of tracers for the visualization of activated fibroblasts for the evaluation of the activity of lung fibroses: in animal models with lung fibrosis and patients with lung fibrosis a PET/CT with radioactive labelled FAPI will be performed, with the goal to identify the patients at risk for an activated fibrosis and to react with the appropriate treatment at an early stage.
